Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticlePROCEEDINGS OF THE 21st ANNUAL MEETING OF THE SOCIETY OF BIOTHERAPEUTIC APPROACHES

Construction of Anti-HER2 Recombinants as Targeting Modules for a Drug-delivery System Against HER2-positive Cells

QING TANG, MASAYOSHI ONITSUKA, ATSUSHI TABATA, TOSHIFUMI TOMOYASU and HIDEAKI NAGAMUNE
Anticancer Research July 2018, 38 (7) 4319-4325; DOI: https://doi.org/10.21873/anticanres.12731
QING TANG
1Department of Biological Science and Technology, College of Life and Materials Systems Engineering, Graduate School of Advanced Technology and Science, Tokushima University, Tokushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAYOSHI ONITSUKA
1Department of Biological Science and Technology, College of Life and Materials Systems Engineering, Graduate School of Advanced Technology and Science, Tokushima University, Tokushima, Japan
2Department of Bioengineering, Division of Bioscience and Bioindustry, Graduate School of Technology, Industrial and Social Sciences, Tokushima University, Tokushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ATSUSHI TABATA
1Department of Biological Science and Technology, College of Life and Materials Systems Engineering, Graduate School of Advanced Technology and Science, Tokushima University, Tokushima, Japan
2Department of Bioengineering, Division of Bioscience and Bioindustry, Graduate School of Technology, Industrial and Social Sciences, Tokushima University, Tokushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOSHIFUMI TOMOYASU
1Department of Biological Science and Technology, College of Life and Materials Systems Engineering, Graduate School of Advanced Technology and Science, Tokushima University, Tokushima, Japan
2Department of Bioengineering, Division of Bioscience and Bioindustry, Graduate School of Technology, Industrial and Social Sciences, Tokushima University, Tokushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDEAKI NAGAMUNE
1Department of Biological Science and Technology, College of Life and Materials Systems Engineering, Graduate School of Advanced Technology and Science, Tokushima University, Tokushima, Japan
2Department of Bioengineering, Division of Bioscience and Bioindustry, Graduate School of Technology, Industrial and Social Sciences, Tokushima University, Tokushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nagamune@tokushima-u.ac.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 38 no. 7 4319-4325
DOI 
https://doi.org/10.21873/anticanres.12731
PubMed 
29970568

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received April 11, 2018
  • Revision received May 16, 2018
  • Accepted May 17, 2018
  • Published online July 3, 2018.

Copyright & Usage 
Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

Author Information

  1. QING TANG1,
  2. MASAYOSHI ONITSUKA1,2,
  3. ATSUSHI TABATA1,2,
  4. TOSHIFUMI TOMOYASU1,2 and
  5. HIDEAKI NAGAMUNE1,2⇑
  1. 1Department of Biological Science and Technology, College of Life and Materials Systems Engineering, Graduate School of Advanced Technology and Science, Tokushima University, Tokushima, Japan
  2. 2Department of Bioengineering, Division of Bioscience and Bioindustry, Graduate School of Technology, Industrial and Social Sciences, Tokushima University, Tokushima, Japan
  1. Correspondence to: Hideaki Nagamune, Department of Bioengineering, Division of Bioscience and Bioindustry, Graduate School of Technology, Industrial and Social Sciences, Tokushima University, 2-1, Minamijosanjima-cho, Tokushima, 770-8513, Japan. Tel/Fax: +81 886567525, e-mail: nagamune{at}tokushima-u.ac.jp
View Full Text

Cited By...

  • 4 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Anticancer Research: 38 (7)
Anticancer Research
Vol. 38, Issue 7
July 2018
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Construction of Anti-HER2 Recombinants as Targeting Modules for a Drug-delivery System Against HER2-positive Cells
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 19 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Construction of Anti-HER2 Recombinants as Targeting Modules for a Drug-delivery System Against HER2-positive Cells
QING TANG, MASAYOSHI ONITSUKA, ATSUSHI TABATA, TOSHIFUMI TOMOYASU, HIDEAKI NAGAMUNE
Anticancer Research Jul 2018, 38 (7) 4319-4325; DOI: 10.21873/anticanres.12731

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Construction of Anti-HER2 Recombinants as Targeting Modules for a Drug-delivery System Against HER2-positive Cells
QING TANG, MASAYOSHI ONITSUKA, ATSUSHI TABATA, TOSHIFUMI TOMOYASU, HIDEAKI NAGAMUNE
Anticancer Research Jul 2018, 38 (7) 4319-4325; DOI: 10.21873/anticanres.12731
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Functional diversification of hybridoma produced antibodies by CRISPR/HDR genomic engineering
  • Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering
  • Google Scholar

More in this TOC Section

PROCEEDINGS OF THE 21st ANNUAL MEETING OF THE SOCIETY OF BIOTHERAPEUTIC APPROACHES

  • Phagocytic Activation of Macrophages with Serum MAF Depends on Engulfment Efficiency and Not Migratory Activity
  • Seizures and Tumor Progression in Glioma Patients with Uncontrollable Epilepsy Treated with Perampanel
Show more PROCEEDINGS OF THE 21st ANNUAL MEETING OF THE SOCIETY OF BIOTHERAPEUTIC APPROACHES

Experimental Studies

  • Phagocytic Activation of Macrophages with Serum MAF Depends on Engulfment Efficiency and Not Migratory Activity
  • Seizures and Tumor Progression in Glioma Patients with Uncontrollable Epilepsy Treated with Perampanel
  • Docosahexaenoic Acid Potentiates the Anticancer Effect of the Menadione/Ascorbate Redox Couple by Increasing Mitochondrial Superoxide and Accelerating ATP Depletion
Show more Experimental Studies

Similar Articles

Keywords

  • Drug-delivery system
  • Fab
  • scFv
  • Sortase A
  • trastuzumab
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire